Search Results
Corona, A. H., Nieves, I., Meckes, M., Chamorro, G., Barron, B. L. (2002) Antiviral activity of spirulina maxima against herpes simplex virus type 2. Antivir. Res. 56 , 279–285. Barron B. L
Vírusellenes terápiás lehetőségek COVID–19 fertőzés kezelésére
Antiviral therapies for COVID-19 infections
. pp. 149–150. 9 Martinez, M. A. (2020) Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrobial Agents and Chemotherapy, Vol. 64. No. 9
266 274 Asselah, T., Ripault, M-P., Castelnau, C. és mtsai: The current status of antiviral therapy of chronic hepatitis B. J. Clin. Virol., 2005, 34 , S115
2007 Thio, C. L.: Host genetic factors and antiviral immune responses to hepatitis C virus. Clin. Liver Dis., 2008, 12 , 713
, G., Tomlinson, G., Nishikawa, Y. és mtsai: Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology, 2010, 139 , 1218
: Directly acting antivirals for the treatment of patients with hepatitis C infection: A clinical development update addressing key future challenges. J. Hepatol., 2009, 50 , 184–194. Tillman H
266 274 Asselah, T., Ripault, M.-P., Castelnau, C. et al.: The current status of antiviral therapy of chronic hepatitis B. J. Clin. Virol., 2005, 34 , S115–S
antiviral effects on coxsackievirus B3 (CVB3) and human enterovirus 71 (EV71) infection in vitro. CVB3, a member of the Picornaviridae family, is the most common human pathogen for viral myocarditis that leads to dilated cardiomyopathy, which may cause
. Aronsohn, A., Jensen, D.: Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology, 2011, 53 , 1789–1791. Jensen D. Distributive justice
. Hofer 2008 Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to antiviral combination therapy J. Hepatol. 48 Suppl.1 S28 .
